Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J. 2021 05 26; 11(5):103.

View in: PubMed

subject areas

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Cornea
Corneal Diseases
Disease Management
Humans
Multiple Myeloma
Neoplasm Recurrence, Local
Patient Care Team

authors with profiles

Andrzej Jakubowiak
Asim Farooq